A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC

This study is testing whether adding serplulimab (an immunotherapy drug) to chemotherapy as a "conversion" therapy can shrink tumors enough in patients with advanced non-small cell lung cancer (NSCLC) that surgery becomes possible. The idea is to give this combination first, and if the tumors respond well enough, follow with surgery to try for a cure. **You may be eligible if...** - You are between 18 and 75 years old with confirmed non-small cell lung cancer - Your cancer is at an advanced stage (stage IIIB–IVA with limited spread — "oligometastatic") - You have not yet received any treatment for your lung cancer - After treatment, surgical removal of the main tumor should be feasible - Your overall health is good (ECOG score 0–1) and lung function is sufficient for surgery **You may NOT be eligible if...** - You have already received any cancer treatment - Your disease is too widely spread to potentially be operable even with response to treatment - You have certain genetic mutations that are better treated with targeted therapy first Talk to your doctor to see if this trial is right for you.